Gao Zhenhai, Garcia-Echeverria Carlos, Jensen Michael Rugaard
Novartis Pharma AG, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Curr Opin Drug Discov Devel. 2010 Mar;13(2):193-202.
The development of small molecular mass Hsp90 inhibitors has become an increasingly competitive field of research in recent years. Progress in preclinical and clinical research has provided increasing evidence that Hsp90 represents a promising molecular target for the treatment of cancer and other diseases. Although many challenges remain, recent clinical trial results for the most clinically advanced inhibitors indicate that clinical proof of concept in oncology therapy is achievable, and that Hsp90 inhibitors have the potential to contribute to the collection of anticancer treatments available to clinicians and patients in the near future.
近年来，小分子质量热休克蛋白90（Hsp90）抑制剂的研发已成为竞争日益激烈的研究领域。临床前和临床研究的进展提供了越来越多的证据，表明Hsp90是治疗癌症和其他疾病的一个有前景的分子靶点。尽管仍存在许多挑战，但针对临床上最先进抑制剂的近期临床试验结果表明，肿瘤治疗的临床概念验证是可以实现的，并且Hsp90抑制剂有可能在不久的将来为临床医生和患者提供更多的抗癌治疗手段。
